FDA hands AstraZeneca-Amgen broad approval for asthma antibody, clearing blockbuster path

After last year’s Phase III results, there was little question that the FDA would approve Amgen and AstraZeneca’s long-incubating antibody for asthma, barring any manufacturing delays or shocking statistical snafus. The key question was how many asthma patients would be approved by regulators.

The answer was a lot, it turned...

Click to view original post